12:52 AM
 | 
Aug 21, 2018
 |  BC Extra  |  Clinical News

MC2's non-greasy psoriasis cream superior to Taclonex

MC2 Therapeutics A/S (Horsholm, Denmark) said MC2-01, its non-greasy topical cream formulation of calcipotriene/betamethasone dipropionate, was superior to Taclonex, a marketed formulation of the combination, on the primary and secondary endpoints in a Phase III trial to treat mild to moderate psoriasis. MC2 plans to submit an NDA to FDA in 1H19 for MC2-01, its lead candidate, which...

Read the full 267 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >